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Introduction: Sister chromatid exchanges (SCEs) can be induced by various 
genotoxic treatments, suggesting that SCEs refl ect a DNA repair process and it 
may be a good index for assessment of genomic instability. However, the oc-
currence of genetic instability and in particular, of spontaneous SCEs has been 
strongly linked to cancer. Several chromosomal regions and many genes have 
been implicated in breast cancer.
Materials and Methods: Blood samples were obtained from 31 Iranian breast 
cancer patients and 11 healthy women. SCE was measured in peripheral blood 
lymphocytes by adding to Ham’sF10 medium in presence of PHA, BrdU 
(5-bromo-deoxy Uridine) fl uorochrome Hoechst 33258, exposure to UV light 
and Giemsa staining. Then, SCE frequencies of patient and control groups were 
compared by the Mann-Withney U-test. 
Results: Signifi cantly difference was observed between two groups (p<0.001). 
Conclusion: This study indicates that SCE can be used as a risk biomarker for 
breast cancer.




SCE, breast cancer, peripheral blood, 
BrdU.
INTRODUCTION                           
Breast cancer is the most prev-
alent malignancy in women, 
with about one million cases 
diagnosed annually worldwide. 
Many environmental and bio-
logical factors have involved 
in progression of this cancer. Thus, be-
cause of genetic heterogeneity, molecu-
lar genetic testing is very diffi cult to 
identify its causes. For example, vari-
ous types of molecular methods have 
been used for detection of BRCA gene 
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mutations and more recently, CGH and 
multicolor fl uorescence in situ hybrid-
ization (M-FISH) have been applied to 
identify many gains and losses of DNA 
sequences and loci in breast tumors.1
The phenomenon of sister chromatid 
exchange (SCE) is a symmetrical ex-
change of apparently identical portions 
of chromosomes and involves DNA 
breakage and reunion mechanism2. Cy-
tological assessment of SCE levels in 
peripheral blood lymphocytes is used 
as an index of the mutagenic poten-
tial of environmental factors such as 
various mutagenic and/or carcinogenic 
chemicals like mitomycin C3-8 and pos-
sible therapeutic agents like resveratrol9 
and this test is widely used as a reliable 
and sensitive indicator of chromosome 
(DNA) instability, since the SCE pat-
terns can reveal a general genomic 
instability8,10. The increased frequency 
of spontaneous SCE has been report-
ed in patient with various neoplastic 
diseases10,11. Variations in DNA repair 
mechanisms or detoxifying associated 
with cancer12. Also, the sister chroma-
tid exchange frequency was found to be 
signifi cantly higher in individuals with 
Werner syndrome, Bloom’s syndrome 
and myelodysplastic disease than in 
their control groups. These diseases are 
known to be associated with genom-
ic instability13. More importantly, 10 
SCEs occur spontaneously in normally 
cycling human cells.14,15
Whereas tumor markers have been 
widely investigated, there have been 
few studies on the predictive value of 
cytogenetic biomarkers for cancer de-
velopment. The aim of this study was to 
assessment of SCE frequency in Iranian 
breast cancer patients.
MATERIALS AND METHODS              
Patient and Control Samples:
This research was done in Tehran 
University of Medical Sciences, Iran. 
Thirty one affected females with breast 
cancer between 26 and 65 years of age 
were examined as the study group. On 
the other hand, 11 healthy women as the 
control group were studied. Heparinized 
blood was obtained by venipuncture of 
an arm from samples and informed con-
sent was obtained from all participants. 
They did not smoke and were not taking 
drugs for medical or other reasons.
Slide Preparation and SCE Test:
Whole blood cultures were initiated by 
adding 10 drops of blood to each cul-
ture fl ask containing 5 mL of Ham’sF10 
supplemented with 15% fetal calf se-
rum, 4 mM L-glutamine, 100 units/
mL penicillin, 100 g/mL streptomy-
cinand0.1 mL of phytohemagglutinin 
(PHA) (Biochrom) for 72 hrs at 37 ºC. 
5-Bromodeoxyuridine (BrdU) (Sigma, 
St. Louis, MO, USA) was added at a 
fi nal concentration of 10 μg/ml for the 
last 48 hrs of incubation, during which 
time the culture tubes were kept in the 
dark to minimize SCE induction by 
photolysis of BrdU-substituted DNA. 
Colcemide (0.02 mg/ml) was added for 
the fi nal 40 min of culture. Harvesting 
of cells and slide preparation were ac-
complished by the standard method16. 
The slides were stained for 12 min in a 
0.5 μg/ml solution of the fl uorochrome 
Hoechst 33258, exposed to UV light 
(distance approximately 12 cm) for a 
minimum of 2 hrs in a sodium phos-
phate buffer (0.3 M; pH 7.0), rinsed and 
stained with 4% Giemsa at pH 6.8.
The microscope slides were studied. 
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The number of SCEs/chromosome was 
calculated for each individual. SCE 
frequencies (number per chromosome) 
were determined in cultures from dif-
ferent groups. Thirty metaphases were 
studied for each individual; 930 and 
330 metaphases were analyzed in 31 
patients and 11 healthy individuals, re-
spectively.
Statistical Analysis:
The distribution of the number of SCEs/
chromosome was examined for two 
groups. The mean SCE frequency was 
evaluated and compared to the control 
group statistically by the Mann-With-
ney U-test.
RESULTS                                                                    
The mean frequencies of spontaneous 
SCE per metaphase were 6.67 ±1,42 
and 4.64 ± 1.19 in patients and control 
group, respectively. Spontaneous SCE 
values in the study and control groups 
were found statistically signifi cant at 
the end of the evaluation (p<0.001) 
(Table 1). 
                                  
Table 2 shows the mean SCE frequen-
cies in patients with breast cancer in 
previous studies and comparison with 
present study. One metaphase with 
8 SCE of patient has been shown in 
(Figure. 1)
DISCUSSION                                                 
The application of cytogenetic biomark-
ers (chromosomal aberrations, sister 
chromatid exchanges and micronuclei) 
is critical for health risk assessment af-
ter environmental or occupational ex-
posure. We studied spontaneous SCE 
frequencies in the lymphocyte cultures 
of 31 breast cancer patients and 11 
controls in Iranian population. Higher 
spontaneous SCE were observed in 
Table 1: Mean frequencies of SCE per 












6.67+1.4226-65930/31      Patients
4.64+1.1928-60330/11Control
Table 2: Comparison of mean SCE fre-












5.1± 0.777.21± 0.35Sholnick et al.17
4.7± 0.186.98± 0.32Livingston et al.18
6.28± 0.877.77± 0.41Adhvaryu et al.19
4.62± 0.145.96± 0.19Husain et al.20
4.65± 0.195.8± 0.23Dhillon et al.11
4.64± 0.076.67± 0.05Present study
Fig. 1: Sister chromatid exchange.
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the cells of patients compared with 
the controls (p< 0.001). Similar eleva-
tions of spontaneous lymphocytic SCE 
rates have been reported by others for 
patients with malignant lymphoma21, 
cutaneous malignant melanoma22, lung 
cancer23 and uterine cervix cancer24,25 
and breast cancer.10,11
However, SCE provides an easy, repro-
ducible and good index for monitoring 
DNA damage and DNA repair status3,26. 
The analysis of sister chromatid ex-
changes is a sensitive tool for evaluat-
ing DNA lesions of the kind that may 
lead to cancer development and has 
been well accepted for studying carci-
nogenic and/or mutagenic potentials of 
chemical as well as physical agents6-9,25. 
In human neoplasms, spontaneous SCE 
study has been used for various pur-
poses27 and it may indicate a promising 
future for treatment monitoring.
Although genomic instability is a com-
mon feature of cancers, its exact mech-
anism is not understood yet; however, 
data support the hypothesis that chro-
mosome instability may be related to the 
development of neoplasia. This hypoth-
esis is supported by the fact that spon-
taneous SCE frequencies from various 
cancers have shown higher.8-10,20,21,28
Various factors have been suggested as 
capable of infl uencing the frequency 
of SCEs in human lymphocyte cul-
tures. These include possible techni-
cal artifacts (e.g., the concentration of 
BrdU, the number of lymphocytes in 
the sample and exposure to light fol-
lowing incorporation of the analog) as 
well as biologically more important 
considerations such as heavy cigarette 
smoking, the presence of a malignancy 
and/or chemotherapeutic treatment and 
occupational exposure to agents that 
induce SCEs. Although the molecular 
mechanisms responsible for the produc-
tion of SCEs are not still fully under-
stood, recently, it was proposed that a 
double strand break (DSB) generates a 
‘signal’ which triggers the cell to make 
a recombinogenic exchange in a looped 
structure either within (intra-chroma-
tid) or between (inter-chromatid) sister 
chromatids.29
Our results indicates that the increased 
mean SCE frequency in breast cancer 
patients compared with the controls 
(p< 0.001), suggesting SCE can be used 
a preclinical marker for early detection 
of breast cancer.
In wild-type mammalian cells, the re-
pair of DSB by homologous recombi-
nation uses mainly the sister chromatid 
as a template30. BRCA1 and BRCA2 
proteins have an important role in the 
control of homologous recombination 
and double strand break repair31. Previ-
ous data support this hypothesis that en-
hanced sensitivity of peripheral blood 
lymphocytes from women carrying a 
BRCA1 mutation towards the mutagen-
ic effects of various cytostatics11. Pro-
teins involved in DNA repair pathways 
such as p53, BRCA1 and BRCA2 are 
involved in tumor initiation and its pro-
gression. Since, SCE is due to defect in 
repairing of the damaged DNA, the de-
fect can be in any of the repair pathways 
which are associated with cancer devel-
opment and because these proteins have 
important roles in breast cancer28, it can 
imply that SCE may cause breast can-
cer. Further investigations are needed to 
be carried out on various types of can-
cers in order to resolve the mechanism 
involving SCE and genomic instability 
associated cancers.
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